Harrow Health, Inc. (NASDAQ:HROW) Major Shareholder Buys $192,759.75 in Stock

Harrow Health, Inc. (NASDAQ:HROWGet Rating) major shareholder Opaleye Management Inc. acquired 28,557 shares of the business’s stock in a transaction on Tuesday, April 12th. The shares were bought at an average price of $6.75 per share, with a total value of $192,759.75. Following the completion of the transaction, the insider now directly owns 3,165,000 shares of the company’s stock, valued at $21,363,750. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Opaleye Management Inc. also recently made the following trade(s):

  • On Friday, January 28th, Opaleye Management Inc. acquired 6,343 shares of Harrow Health stock. The shares were bought at an average price of $6.89 per share, with a total value of $43,703.27.

Shares of NASDAQ HROW traded up $0.05 during midday trading on Wednesday, reaching $6.78. The company’s stock had a trading volume of 168,946 shares, compared to its average volume of 67,070. The company has a debt-to-equity ratio of 6.56, a quick ratio of 5.81 and a current ratio of 6.24. Harrow Health, Inc. has a fifty-two week low of $6.58 and a fifty-two week high of $12.99. The business’s 50 day moving average price is $7.47 and its two-hundred day moving average price is $8.70. The company has a market cap of $183.26 million, a P/E ratio of -10.07 and a beta of 0.96.

Harrow Health (NASDAQ:HROWGet Rating) last released its quarterly earnings results on Thursday, March 10th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.35). Harrow Health had a negative net margin of 24.84% and a positive return on equity of 4.36%. During the same quarter last year, the company earned $0.07 earnings per share. Sell-side analysts forecast that Harrow Health, Inc. will post 0.04 earnings per share for the current fiscal year.

Separately, Zacks Investment Research downgraded shares of Harrow Health from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 15th.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Opaleye Management Inc. raised its position in shares of Harrow Health by 4.6% in the third quarter. Opaleye Management Inc. now owns 3,285,000 shares of the company’s stock valued at $29,861,000 after buying an additional 145,000 shares in the last quarter. Wasatch Advisors Inc. increased its stake in Harrow Health by 17.1% in the fourth quarter. Wasatch Advisors Inc. now owns 665,304 shares of the company’s stock valued at $5,748,000 after acquiring an additional 97,237 shares during the last quarter. Acadian Asset Management LLC increased its stake in Harrow Health by 2.7% in the fourth quarter. Acadian Asset Management LLC now owns 537,540 shares of the company’s stock valued at $4,643,000 after acquiring an additional 14,053 shares during the last quarter. BlackRock Inc. increased its stake in Harrow Health by 3.9% in the fourth quarter. BlackRock Inc. now owns 431,267 shares of the company’s stock valued at $3,725,000 after acquiring an additional 16,381 shares during the last quarter. Finally, Invenire Partners LP bought a new position in Harrow Health in the fourth quarter valued at approximately $2,830,000. Institutional investors own 43.57% of the company’s stock.

About Harrow Health (Get Rating)

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.

Recommended Stories

Insider Buying and Selling by Quarter for Harrow Health (NASDAQ:HROW)

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.